1. Home
  2. TNON vs XRTX Comparison

TNON vs XRTX Comparison

Compare TNON & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenon Medical Inc.

TNON

Tenon Medical Inc.

HOLD

Current Price

$0.91

Market Cap

4.8M

Sector

Health Care

ML Signal

HOLD

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

HOLD

Current Price

$0.84

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNON
XRTX
Founded
2012
2011
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical Specialities
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
3.9M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
TNON
XRTX
Price
$0.91
$0.84
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $6.00
N/A
AVG Volume (30 Days)
95.4K
★ 140.0K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 84.90
N/A
EPS
N/A
★ N/A
Revenue
★ $3,944,000.00
N/A
Revenue This Year
$44.38
N/A
Revenue Next Year
$39.49
$392.31
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 20.35
N/A
52 Week Low
$0.96
$0.35
52 Week High
$40.95
$3.60

Technical Indicators

Market Signals
Indicator
TNON
XRTX
Relative Strength Index (RSI) 22.15 34.58
Support Level N/A $0.36
Resistance Level $4.18 $2.23
Average True Range (ATR) 0.17 0.16
MACD -0.02 0.03
Stochastic Oscillator 4.65 0.00

Price Performance

Historical Comparison
TNON
XRTX

About TNON Tenon Medical Inc.

Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Share on Social Networks: